Kurve Therapeutics, Inc.
Tom McDowell has a diverse and extensive work experience spanning several industries. Tom is currently the Chief Operating Officer/Chief Financial Officer at Kurve Therapeutics, Inc., where they are responsible for protecting company assets and managing contracts and obligations. Prior to their current role, Tom served as the Chairman at Concorso Italiano, leading the organization of the world's largest exhibition of exotic Italian cars. Tom also worked as the Corporate Controller at Pineapple Hospitality, where they managed contracts, protected assets, and measured growth. Additionally, Tom worked as a Consultant at CFO Selections, specializing in contract management, asset protection, and growth measurement. Their earlier experience includes serving as the Executive Vice President & Chief Financial Officer at Windswept Capital LLC, where they played a pivotal role in building the company and completing high-value transactions in middle-market M&A. Overall, Tom McDowell's work experience demonstrates their expertise in finance, operations, contract management, and asset protection.
Tom McDowell attended the University of Southern California from 1977 to 1981, where they earned a Bachelor of Science degree in Business Administration.
This person is not in any teams
This person is not in any offices
Kurve Therapeutics, Inc.
Kurve Therapeutics engages in the development of treatments for neurodegenerative diseases. Its drug delivery technology is designed to target the most difficult part of the treatment process — getting medication through the blood-brain barrier and into the brain.Through the development of their patented Controlled Particle Dispersion technology,Kurve Therapeutics aims to reshape the landscape of cognitive aging, neurodegenerative diseases, and related disorders. Its next-generation technology has been shown to deliver up to 30x more disease-modifying medication directly to the brain than infusions in several Phase II studies. This allows for significant dose flexibility away from toxic doses for a safer, more efficacious therapy. While traditional treatment options continually prove ineffective at stopping neurodegenerative disease progression and often lead to toxicity or continued decline, Kurve is developing a new disease-modifying approach.